Dr. David Berman is the Director of the Queen’s Cancer Research Institute (2015- present) and a Professor of Pathology and Molecular Medicine at Queen’s University. He practices genitourinary surgical pathology and runs a research laboratory focused on biomarkers that guide management decisions for patients with prostate and bladder cancer. He also chairs the Research Advisory Committee for Prostate Cancer Canada as well as the Genitourinary Correlative Science Committee for the Canadian Cancer Trials Group. Prior to moving to Queen’s in 2012, Dr. Berman’s clinical practice and laboratory were located at The Johns Hopkins Medical Institutions in Baltimore, Maryland.

Dr. Berman received his Doctor of Medicine and PhD degrees from UT Southwestern in Dallas Texas. He completed anatomic residency training and a postdoctoral fellowship in Molecular BIology and Genetics at Johns Hopkins.

Dr. Berman’s research work ranges from mechanistic, genomic, bioinformatic, and pharmacologic investigation of oncogenic signaling pathways to practical advances in cancer diagnostics.